See more : Meiji Holdings Co., Ltd. (MEJHY) Income Statement Analysis – Financial Results
Complete financial analysis of Biotricity, Inc. (BTCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotricity, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- FedEx Corporation (FDX.SW) Income Statement Analysis – Financial Results
- Bolak Company Limited (002760.KS) Income Statement Analysis – Financial Results
- Willow Biosciences Inc. (WLLW.TO) Income Statement Analysis – Financial Results
- OncoCyte Corporation (0KCC.L) Income Statement Analysis – Financial Results
- Hang Lung Group Limited (HNLGF) Income Statement Analysis – Financial Results
Biotricity, Inc. (BTCY)
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M | 398.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.71M | 4.20M | 3.08M | 2.11M | 931.95K | 338.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K | 59.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.27% | 56.46% | 59.74% | 37.60% | 34.26% | 15.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.57M | 3.23M | 2.74M | 2.06M | 1.36M | 1.31M | 1.76M | 1.14M | 1.14M | 23.20K | 53.60K |
| General & Administrative | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Other Expenses | 0.00 | -181.94K | -1.14M | -67.10K | 16.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.22K | -1.15K |
| Operating Expenses | 17.18M | 20.85M | 21.31M | 14.62M | 11.42M | 8.65M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Cost & Expenses | 20.89M | 25.05M | 24.39M | 16.74M | 12.35M | 8.99M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.19M | 2.58M | 10.57M | 2.48M | 92.42K | 0.00 | 879.42K | 1.18M | 59.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.95K | 346.26K | 68.34K | 347.12K | 148.76K | 8.58M | 7.72M | 5.94M | 9.05K | 810.00 | 1.15K |
| EBITDA | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M | -8.59M | 0.00 | -5.94M | -5.12M | 0.00 | -89.92K |
| EBITDA Ratio | -73.75% | -161.69% | -233.65% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -15.59M | -17.88M | -13.42M | -10.91M | -8.59M | -7.72M | -5.94M | -5.13M | -90.41K | -91.07K |
| Operating Income Ratio | -73.18% | -161.75% | -233.68% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.27M | -3.25M | -12.39M | -2.78M | -136.26K | 0.00 | -900.00K | -1.87M | -55.85K | 7.00 | 0.00 |
| Income Before Tax | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Income Before Tax Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.40M | 9.43M | 2.07M | -39.41K | -171.86K | -6.84M | -4.76M | 50.82K | -810.00 | -1.15K |
| Net Income | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Net Income Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| EPS Diluted | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert
REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the...
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Biotricity Inc. (BTCY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum...
Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud
Biotricity's AI automation engine has already proven to increase operational efficiency and support growth, evidenced by the Company's recent margin improvement The Healthcare AI Market is projected to soar to $208.2 billion and remote patient monitoring (RPM) market anticipated to...
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Biotricity Inc. (BTCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotricity Partners with a Second Top Group Purchasing Organization - Positions Company for Expanded Market Access to 1 out of every 2 Hospitals in America
REDWOOD CITY, CA / ACCESSWIRE / March 5, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced its partnership with another of the nation's top Group Purchasing Organizations (GPOs)....
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March...
Biotricity Receives Health Canada Clearance for Biotres
Well Positioned to Enter US $1.56 Billion Canadian Cardiology Devices Market REDWOOD CITY, CA / ACCESSWIRE / February 29, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, proudly announced its...
Biotricity, Inc. (BTCY) Q3 2024 Earnings Call Transcript
Biotricity, Inc. (BTCY) Q3 2024 Earnings Call Transcript
Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024
Topline growth with better quality revenue mix Increase in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenue Improved margins Lower costs with improved selling expense Stronger path to breakeven REDWOOD CITY, CA /...
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports